Anurag Relan
Overview
Explore the profile of Anurag Relan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
FitzPatrick A, Chin A, Nirenberg S, Cunningham-Rundles C, Sacco K, Perlmutter J, et al.
Front Immunol
. 2025 Feb;
15:1508780.
PMID: 39906746
Introduction: Patients with activated PI3Kδ syndrome (APDS) may elude diagnoses for nearly a decade. Methods to hasten the identification of these patients, and other patients with inborn errors of immunity...
2.
Rao V, Sediva A, Dalm V, Plebani A, Schuetz C, Shcherbina A, et al.
Clin Immunol
. 2024 Nov;
270:110400.
PMID: 39561927
Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an ultra-rare, progressive genetic disease, characterised by immune deficiency and dysregulation, affecting individuals from birth. In a 12-week phase III randomised placebo-controlled...
3.
Rao V, Kulm E, Sediva A, Plebani A, Schuetz C, Shcherbina A, et al.
J Allergy Clin Immunol
. 2023 Oct;
153(1):265-274.e9.
PMID: 37797893
Background: Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS; or p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency) is an inborn error of immunity caused by PI3Kδ hyperactivity. Resultant immune...
4.
Rao V, Webster S, Sediva A, Plebani A, Schuetz C, Shcherbina A, et al.
Blood
. 2022 Nov;
141(9):971-983.
PMID: 36399712
Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an inborn error of immunity with clinical manifestations including infections, lymphoproliferation, autoimmunity, enteropathy, bronchiectasis, increased risk of lymphoma, and early mortality. Hyperactive...
5.
Valerieva A, Staevska M, Grivcheva-Panovska V, Jesenak M, Kohalmi K, Hrubiskova K, et al.
World Allergy Organ J
. 2021 May;
14(4):100535.
PMID: 33995818
Background: Hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling attacks. A European treatment registry was established to review the adverse event profile and...
6.
Hayes S, Farrell C, Relan A, Anderson J
Ann Allergy Asthma Immunol
. 2021 Feb;
126(6):707-712.
PMID: 33609769
Background: Recombinant human C1 esterase inhibitor (rhC1-INH) is indicated in the United States for the treatment of acute hereditary angioedema (HAE) attacks in adolescents and adults; it is also indicated...
7.
Bernstein J, Tyson C, Relan A, Adams P, Magar R
J Manag Care Spec Pharm
. 2019 Dec;
26(2):203-210.
PMID: 31841366
Background: Hereditary angioedema (HAE) is a rare C1-inhibitor (C1-INH) deficiency disease. Low levels of functional C1-INH can lead to recurrent attacks of severe swelling occurring in areas such as the...
8.
Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy
Moldovan D, Bernstein J, Hakl R, Porebski G, Poarch K, Lumry W, et al.
J Allergy Clin Immunol Pract
. 2019 Jun;
7(8):2938-2940.
PMID: 31170541
No abstract available.
9.
Reshef A, Grivcheva-Panovska V, Kessel A, Kivity S, Klimaszewska-Rembiasz M, Moldovan D, et al.
Pediatr Allergy Immunol
. 2019 Apr;
30(5):562-568.
PMID: 30993784
Background: Attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INH-HAE) usually begin during childhood or adolescence. However, limited data are available regarding indications and modalities of treatment...
10.
Baker J, Bernstein J, Harper J, Relan A, Riedl M
Allergy Asthma Proc
. 2018 Jun;
39(5):359-364.
PMID: 29954477
Background: Hereditary angioedema (HAE) may occur at or spread to multiple anatomic locations during an acute attack. Recombinant human C1 esterase inhibitor (rhC1-INH) is approved for treating acute HAE attacks....